Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 501 to 525 of 921

TitleReference numberPublishedLast updated
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Drug-eluting stents for the treatment of coronary artery diseaseTA152
Guidance on the use of coronary artery stentsTA71
Siponimod for treating secondary progressive multiple sclerosisTA656
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Galcanezumab for preventing migraineTA659
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Eculizumab for treating refractory myasthenia gravis (terminated appraisal)TA636
Ranibizumab for treating diabetic retinopathy (terminated appraisal)TA637

Results per page

  1. 10
  2. 25
  3. 50
  4. All